Board of Directors
Robert Nelsen has served as a member of our board of directors since October 2015. Mr. Nelsen is a co-founder and has served as a Managing Director of ARCH Venture Partners since 1994. Mr. Nelsen currently serves as a member of the boards of directors of public biopharmaceutical companies Agios Pharmaceuticals, Inc., Juno Therapeutics, Inc., and Syros Pharmaceuticals Inc. Mr. Nelsen also currently serves on the boards of directors of the biotechnology companies Arivale Inc., Denali Therapeutics Inc., Encoded Genomics, Inc., Ensemble Discovery Corp., and as Chairman of the board of directors of Hua Medicine. Previously, Mr. Nelsen served on the boards of directors of a number of public biotechnology companies including Bellerophon Therapeutics, Inc., Fate Therapeutics, Inc., Kythera, NeurogesX, Inc. and Sage Therapeutics Inc. He previously served as a trustee of the Fred Hutchinson Cancer Research Institute and the Institute for Systems Biology, and as a member of the board of directors of the National Venture Capital Association. Mr. Nelsen holds a B.S. from the University of Puget Sound with majors in Economics and Biology and an M.B.A. from the University of Chicago.